Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Px563L and RPA563 in Healthy Adults
NCT02655549Phase 1Completed
- Sponsor
- Pfenex Inc.
- Start
- Dec 2015
- Primary completion
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes, Recombinant Protein Vaccines, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Px563L and RPA563 in anthrax (3 cohorts), sponsored by Pfenex Inc. Primary endpoint: Adverse Events at 393 days. Started Dec 2015; status: completed.
02
Drugs
Px563LRPA563
03
Conditions
anthrax
Beyond the preview
Go deeper on NCT02655549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02655549.